DV
Dividend Vision

CPMV — Mosaic Immunoengineering Inc

Mosaic Immunoengineering Inc (CPMV)

Its deepest 1-year drawdown was 94.9%.

Mosaic ImmunoEngineering is a development-stage biotechnology company founded in 2020 that focuses on advancing immunotherapies for cancer treatment through new product candidates and platforms. The company does not currently distribute dividends. Mosaic ImmunoEngineering appeals to investors seeking exposure to early-stage biotech development rather than current income.

CPMV key facts

Asset type
Stock
Asset class
Equity
Inception date
04/04/1994
Last close
$0.06
Market cap
$441,770
Average volume
0.0
Ex-dividend date
03/02/2007
Payment date
12/02/2020
Beta
-0.813
Payout ratio
0.0
Forward P/E
10.8108
EPS
$-0.09